NCT00628394View on ClinicalTrials.gov

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

PHASE4CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Cognition in Schizophrenia
Interventions
DRUG

Atomoxetine

40mg 2po qam

DRUG

Placebo

40mg 2po qam

Trial Locations (1)

75390

The University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Stanley Medical Research Institute

OTHER

lead

University of Texas Southwestern Medical Center

OTHER

NCT00628394 - Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation | Biotech Hunter | Biotech Hunter